Professor Richard Gray
Professor of Medical Statistics
- Clinical Trial Service Unit and Epidemiological Studies Unit
Professor Richard Gray completed degrees in physics and statistics at the University of Oxford before beginning his medical statistics career in CTSU, where he worked for 20 years researching the causes of, and best treatments for, cardiovascular diseases and cancer. He was centrally involved in a number of international collaborative projects on the treatment of cancer, and principal investigator of two of the largest ever cancer trials, QUASAR and aTTom, looking at the treatment of colorectal and breast cancer, respectively.
In 1996 he moved to the University of Birmingham as founding Director of the Birmingham Clinical Trials Unit, leading clinical trial, systematic review and methodological research across a wide range of diseases such as neurodegenerative disorders that are common, but less well-investigated than cancer and cardiovascular disease. Landmark studies included the AD2000 trial of donepezil and aspirin in Alzheimer’s and PD MED, comparing different drugs in Parkinson’s disease. Trials in surgical oncology are another particular focus, including FOxTROT assessing the role of pre-operative chemotherapy in colon cancer.
In 2010 he returned to CTSU as Professor of Medical Statistics. His main research areas here are breast and colorectal cancer and neurodegenerative diseases. New studies include the MADE trial testing whether minocycline delays progress of Alzheimer’s disease and the ATLAS2 trial examining antipsychotic treatment in late-onset psychosis, the first randomised controlled trial in this common condition.
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Barrow P. et al, (2019), Histopathology
Anal fistula plug versus surgeon's preference for surgery for trans-sphincteric anal fistula: the FIAT RCT.
Jayne DG. et al, (2019), Health Technol Assess, 23, 1 - 76
Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
Gray R. and Trialists EBC., (2019), CANCER RESEARCH, 79
Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials
Dodwell D. et al, (2019), CANCER RESEARCH, 79
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
Howard R. et al, (2018), Health Technol Assess, 22, 1 - 62